XML 71 R56.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisition of KCG - Narrative (Details) - USD ($)
1 Months Ended 12 Months Ended
Aug. 10, 2017
Jul. 21, 2017
Jul. 20, 2017
May 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Business Acquisition [Line Items]            
Aggregate purchase price           $ 735,974,000
Employee compensation expense           6,400,000
Annual incentive compensation payments           35,300,000
Goodwill         $ 836,583,000 844,883,000
Deferred tax assets         200,359,000 125,760,000
Market Making            
Business Acquisition [Line Items]            
Goodwill     $ 96,200,000   755,292,000 755,292,000
Execution Services            
Business Acquisition [Line Items]            
Goodwill     $ 32,100,000   $ 81,291,000 $ 89,591,000
Senior Secured Notes Due 2020            
Business Acquisition [Line Items]            
Interest rate   6.875%        
Redemption price as a percentage of the principal amount   103.438%        
Face amount   $ 465,000,000.0        
Temasek Investment            
Business Acquisition [Line Items]            
Other offering costs $ 7,800,000          
Class A            
Business Acquisition [Line Items]            
Common stock, par value (in dollars per share)         $ 0.00001 $ 0.00001
Number of shares of stock issued       10,518,750    
Employee compensation expense         $ 11,200,000 $ 11,000,000
Class A | NIH Investment Agreement            
Business Acquisition [Line Items]            
Number of shares of stock issued 338,124          
Aggregate purchase price $ 5,200,000          
KCG            
Business Acquisition [Line Items]            
Common stock, par value (in dollars per share)     $ 0.01      
Right to receive cash (in dollars per share)     $ 20.00      
Cash purchase price     $ 1,400,000,000      
Fair value (in dollars per share)     $ 20.00      
Goodwill     $ 128,286,000      
Deferred tax assets     $ 23,900,000      
KCG | NIH Investment Agreement            
Business Acquisition [Line Items]            
Number of shares of stock issued     39,725,979      
Aggregate purchase price     $ 613,500,000      
KCG | Class A | Aranda            
Business Acquisition [Line Items]            
Number of shares of stock issued     6,346,155      
Aggregate purchase price     $ 99,000,000      
KCG | Class A | Temasek Investment            
Business Acquisition [Line Items]            
Number of shares of stock issued 1,666,666          
Aggregate purchase price $ 26,000,000          
KCG | Class A | NIH Investment Agreement            
Business Acquisition [Line Items]            
Number of shares of stock issued 338,124          
Aggregate purchase price $ 5,200,000